4-IBBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine

Journal of Immunology

Volumn 162, Issue 8, 1999, Pages 5003-5010

  Guinn, Barbara Ann ^a   DeBenedette, Mark A ^a   Watts, Tania H ^a   Berinstein, Neil L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CANCER VACCINE; B7 ANTIGEN; CD137 LIGAND; CD86 ANTIGEN; CD86 PROTEIN, MOUSE; INTERLEUKIN 2; INTERLEUKIN 4; LEUKOCYTE ANTIGEN; LIGAND; MEMBRANE PROTEIN; TNFSF9 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CARCINOGENICITY; CELL LINE; CYTOLYSIS; FOLLOW UP; IMMUNOGENICITY; IMMUNOPATHOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL CLONE; CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; METHODOLOGY; MIXED LYMPHOCYTE CULTURE; MOLECULAR CLONING; MOUSE MUTANT; PHYSIOLOGY;

4-1BB LIGAND; ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CLONE CELLS; CLONING, MOLECULAR; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; INTERLEUKIN-4; LIGANDS; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOMA, B-CELL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033560179     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Boussiotis, V. A., J. G. Gribben, G. F. Gribben, G. F. Freeman, and L. M. Nadler. 1994. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr. Opin. Immunol. 6:797.
2. Gimmi, C. D., G. J. Freeman, J. G. Gribben, G. Gray, and L. M. Nadler. 1993. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 90:6586.
3. Chen, L., P. S. Linsley, and K. E. Hellstrom. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:482.
4. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
5. Freeman, G. J., A. S. Freeman, J. M. Segil, G. Lee, J. F. Whitman, and L. M. Nadler. 1989. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143:2714.
6. Linsley, P. S., E. A. Clark, and J. A. Ledbetter. 1990. The T cell antigen, CD28, mediates adhesion with B cells by interacting with the activation antigen B7. Proc. Natl. Acad. Sci. USA 87:5031.
7. Azuma, M., D. Ito, H. Yagita, K. Okumura, J. H. Phillips, L. L. Lanier, and C. Somora. 1993. B70 antigen is a second ligand for CTLA4 and CD28. Nature 366:76.
8. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, J. G. Gribben, J. W. Ng, J. Kim, J. W. Goldberg, K. Hathcock, G. Laszlo, L. A. Lombard, S. Wang, G. S. Gray, L. M. Nadler, and A. H. Sharpe. 1993. Murine B7-2, an alternative CTLA4 counter receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178:2185.
9. Razi-Wolf, Z., G. J. Freeman, F. Galvin, B. Benacerraf, L. M. Nadler, and H. Reiser. 1992. Expression and function of the murine B7 antigen, the major costimulatory molecules expressed by peritoneal exudate cells. Proc. Natl. Acad. Sci. USA 89:4210.
10. Inaba, K., M. Witmer-Pack, M. Inaba, K. S. Hathcock, H. Sakuta, M. Azuma, H. Yagita, K. Okumura, P. S. Linsley, and S. Ikehara. 1994. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180:1849.
11. Azuma, M., H. Yessel, J. H. Phillips, H. Spits, and L. L. Lanier. 1993. Functional expression of B7/BB1 on activated T-lymphocytes. J. Exp. Med. 177: 845.
12. Prabhu Das, M. R., S. S. Zamvil, F. Borriello, H. L. Weiner, A. H. Sharpe, and V. K. Kuchroo. 1995. Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T-cells following activation. Eur. J. Immunol. 25:207.
13. Lenschow, D. J., G. H-T. Su, L. A. Zuckerman, N. Nabavi, C. L. Jellis, G. S. Gray, J. Miller, and J. A. Bluestone. 1993. Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA 90: 11054.
14. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Rhodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
15. Gribben, J. G., G. J. Freeman, V. A. Boussiotis, P. Rennert, C. L. Jellis, E. Greenfield, M. Barber, V. A. Restivo, Jr., X. Ke, G. S. Gray, and L. M. Nadler. 1995. CTLA-4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci. USA 92:811.
16. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:501.
17. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4-lg. Immunity 3:541.
18. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270: 985.
19. Kwon, B. S., G. S. Kim, M. B. Prystowsky, D. W. Lancki, D. E. Sabath, and J. L. Pan. 1987. Isolation and characterization of multiple species of T-lymphocyte subset cDNA clones. Proc. Natl. Acad. Sci. USA 84:7473.
20. Goodwin, R. G., W. S. Din, T. Davis-Smith, D. M. Anderson, S. D. Gimpel, T. A. Sato, C. R. Maliszewski, C. I. Brannan, N. G. Copeland, N. A. Jenkins, T. Farrah, R. J. Armitage, W. C. Fanslow, and C. A. Smith. 1993. Molecular cloning of a ligand for the inducible gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol. 23:2361.
21. Alderson, M. R., C. A. Smith, T. W. Tough, T. Davis-Smith, R. J. Armitage, B. Falk, E. Roux, E. Baker, G. R. Sutherland, W. S. Din, and R. G. Goodwin. 1994. Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 24:2219.
22. Pollok, K. E., Y-J. Kim, Z. Zhou, J. Hurtado, K. K. Kim, R. T. Pickard, and B. S. Kwon. 1993. Inducible T-cell antigen 4-1BB. J. Immunol. 150:771.
23. Hurtado, J. C., S. H. Kim, K. E. Pollok, Z. H. Lee, and B. S. Kwon. 1995. Potential role of 4-1BB in T cell activation: comparison with the costimulatory molecule CD28. J. Immunol. 155:3360.
24. DeBenedette, M. A., N. R. Chu, K. E. Pollok, J. Hurtado, W. F. Wade, B. S. Kwon, and T. H. Watts. 1995. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J. Exp. Med. 181:985.
25. Hurtado, J. C., Y-J. Kim, and B. S. Kwon. 1997. Signals through 4-1BB are co-stimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J. Immunol. 158:2600.
26. Pollok, K. E., Y-J. Kim, J. Hurtado, Z. Zhou, K. K. Kim, and B. S. Kwon. 1994. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-μ-primed splenic B cells. Eur. J. Immunol. 24:367.
27. - T lymphocytes by 4-1BB ligand. J. Immunol. 158:551.
28. Mallet, S., and A. N. Barclay. 1991. A new superfamily of cell surface proteins related to the nerve growth factor receptor. Immunol. Today 12:220.
29. Armitage, R. J. 1994. Tumor necrosis factor receptor superfamily members and their ligands. Curr. Opin. Immunol. 6:407.
30. - T cells. J. Immunol. 158:3081.
31. Townsend, S. E., and J. P. Allison. 1993. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368.
32. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K. E. Hellstrom. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
33. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L. M. Nadler, G. J. Freeman, and L. H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatability complex class II molecules. Proc. Natl. Acad. Sci. USA 90:5687.
34. Matulonis, U., C. Dosiou, G. Freeman, C. Lamont, P. Mauch, L. M. Nadler, and J. D. Griffin. 1996. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1126.
35. van Dijk, A. M. C., H. G. Otten, S. M. Vercauteren, F. L. Kessler, M. de Boer, L. F. Verdonck, and G. C. de Gast. 1996. Human B7-1 is more efficient than B7-2 in providing co-stimulation for alloantigen-specific T cells. Eur. J. Immunol. 26:2275.
36. + T lymphocytes in the P815 tumor system in vitro. J. Immunol. 156:465.
37. Martin-Fontecha, A., F. Cavallo, M. Bellone, S. Heltai, G. Iezzi, P. Tornaghi, N. Nabavi, G. Forni, P. Dellabona, and G. Casorati. 1996. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur. J. Immunol. 26:1851.
38. Melero, I., W. W. Shuford, S. A. Newby, A. Aruffo, J. A. Ledbetter, K. E. Hellstrom, R. S. Mittler, and L. Chen. 1997. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3:682.
39. Melero, I., N. Bach, K. E. Hellstrom, A. Aruffo, R. S. Mittler, and L. Chen. 1998. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol. 28: 1116.
40. Kim, K. J., C. Kanellopoulos-Langevin, R. M. Merwin, D. H. Sachs, and R. Asofsky. 1979. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 122:549.
41. Pizzoferrato, E., N. R. Chu, T. S. Hawley, F. H. L. Lieu, B. H. Barber, R. G. Hawley, T. H. Watts, and N. L. Berinstein. 1997. Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12. Hum. Gene Ther. 8:2217.
42. Saoulli, K, S. Y. Lee, J. L. Cannons, W. C. Yeh, A. Santana, M. D. Goldstein, N. Bangia, M. A. DeBenedette, T. W. Mak, Y. Choi, and T. H. Watts. 1998. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J. Exp. Med. 187:1849.
43. Karasuyama, H., and F. Melchers. 1988. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5 using modified cDNA expression vectors. Eur. J. Immunol. 18:97.
44. Goding, J. W. 1983. Monoclonal Antibodies: Principles and Practise. Academic Press, London, pp. 230.
45. Kim, Y-J, S. H. Kim, P. Mantel, and B. S. Kwon. 1998. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cells responses. Eur. J. Immunol. 28:881.
46. Shuford, W. W, K. Klussman, D. D. Tritchler, D. T. Loo, J. Chalupny, A. W. Siadak, T. J. Brown, J. Emswiler, H. Raecho, C. P. Larsen, T. C. Pearson, J. A. Ledbetter, A. Aruffo, and R. S. Mittler. 1997. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186:47.